<p>Prime Medicine（纳斯达克股票代码：PRME - 获取免费报告）在周二的一份研究报告中被华尔街 Zen 的股票研究分析师从 “强烈卖出” 评级上调至 “卖出” 评级。</p>
<p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
<p>PRME 近期成为多份报告的主题。Lifesci Capital 在 3 月 2 日的研究报告中将 Prime Medicine 的股票评级上调至 “强烈买入”。Oppenheimer 在 3 月 12 日的报告中开始覆盖 Prime Medicine 的股票。他们给予该股票 “跑赢大盘” 的评级，并设定了 11.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的共识评级为 “适度买入”，共识目标价为 7.38 美元。</p>
<p><strong>获取我们关于 PRME 的最新报告</strong></p>
<h2>Prime Medicine 股票表现</h2>
<p>周二，PRME 的开盘价为 3.47 美元。Prime Medicine 的 52 周低点为 1.11 美元，52 周高点为 6.94 美元。该公司的 50 日移动平均线为 3.72 美元，200 日移动平均线为 3.90 美元。该公司的市值为 6.2675 亿美元，市盈率为-2.57，贝塔值为 2.35。</p>
<h2>机构投资者对 Prime Medicine 的看法</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。AQR Capital Management LLC 在第一季度将其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前拥有 243,795 股该公司的股票，价值 48.5 万美元，此前在此期间购买了额外的 227,749 股。Jacobs Levy Equity Management Inc. 在第一季度购买了 Prime Medicine 的新头寸，价值约为 101,000 美元。Rhumbline Advisers 在第一季度将其在 Prime Medicine 的持股比例提高了 13.8%。Rhumbline Advisers 目前拥有 81,900 股该公司的股票，价值 163,000 美元，此前在此期间购买了额外的 9,944 股。Creative Planning 在第二季度购买了 Prime Medicine 的新股份，价值约为 25,000 美元。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 Prime Medicine 的持股比例提高了 253.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 119,856 股该公司的股票，价值 29.6 万美元，此前在上个季度购买了额外的 85,938 股。当前 70.37% 的股票由机构投资者持有。</p>
<h2>关于 Prime Medicine</h2>
<p>（获取免费报告）</p>
<p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈性基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，例如插入、缺失、重复或其组合。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票，而不是 Prime Medicine</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中有 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

PRME

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>华尔街禅将 Prime Medicine（NASDAQ:PRME）的评级从 “强烈卖出” 上调至 “卖出”。该股票的共识评级为 “适度买入”，目标价格为 7.38 美元。PRME 的开盘价为 3.47 美元，52 周价格区间为 1.11 美元至 6.94 美元。机构投资者持有该股票的 70.37%，AQR Capital Management 等公司的持股比例显著增加。Prime Medicine 专注于使用 Prime Editing 技术进行治愈性基因疗法</p>

<p>Prime Medicine (NASDAQ:PRME - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a &#34;strong sell&#34; rating to a &#34;sell&#34; rating in a research note issued on Tuesday.</p>
<div class="lb-trans"><p>Prime Medicine（纳斯达克股票代码：PRME - 获取免费报告）在周二的一份研究报告中被华尔街 Zen 的股票研究分析师从 “强烈卖出” 评级上调至 “卖出” 评级。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 的提醒：</p>
</div><p>PRME has been the topic of a number of other reports. Lifesci Capital upgraded shares of Prime Medicine to a &#34;strong-buy&#34; rating in a research note on Monday, March 2nd. Oppenheimer assumed coverage on shares of Prime Medicine in a report on Thursday, March 12th. They issued an &#34;outperform&#34; rating and a $11.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Prime Medicine currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $7.38.</p>
<div class="lb-trans"><p>PRME 近期成为多份报告的主题。Lifesci Capital 在 3 月 2 日的研究报告中将 Prime Medicine 的股票评级上调至 “强烈买入”。Oppenheimer 在 3 月 12 日的报告中开始覆盖 Prime Medicine 的股票。他们给予该股票 “跑赢大盘” 的评级，并设定了 11.00 美元的目标价。一位研究分析师给予该股票 “强烈买入” 评级，四位给予 “买入” 评级，三位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，Prime Medicine 目前的共识评级为 “适度买入”，共识目标价为 7.38 美元。</p>
</div><p><strong>Get Our Latest Report on PRME</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 PRME 的最新报告</strong></p>
</div><h2>Prime Medicine Stock Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 股票表现</h2>
</div><p>PRME opened at $3.47 on Tuesday. Prime Medicine has a fifty-two week low of $1.11 and a fifty-two week high of $6.94. The firm has a 50-day moving average of $3.72 and a 200 day moving average of $3.90. The firm has a market cap of $626.75 million, a P/E ratio of -2.57 and a beta of 2.35.</p>
<div class="lb-trans"><p>周二，PRME 的开盘价为 3.47 美元。Prime Medicine 的 52 周低点为 1.11 美元，52 周高点为 6.94 美元。该公司的 50 日移动平均线为 3.72 美元，200 日移动平均线为 3.90 美元。该公司的市值为 6.2675 亿美元，市盈率为-2.57，贝塔值为 2.35。</p>
</div><h2>Institutional Investors Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>机构投资者对 Prime Medicine 的看法</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Prime Medicine by 1,419.4% during the first quarter. AQR Capital Management LLC now owns 243,795 shares of the company's stock worth $485,000 after purchasing an additional 227,749 shares during the period. Jacobs Levy Equity Management Inc. purchased a new position in shares of Prime Medicine in the first quarter worth about $101,000. Rhumbline Advisers raised its position in shares of Prime Medicine by 13.8% in the first quarter. Rhumbline Advisers now owns 81,900 shares of the company's stock valued at $163,000 after purchasing an additional 9,944 shares during the period. Creative Planning bought a new stake in shares of Prime Medicine in the second quarter valued at approximately $25,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Prime Medicine by 253.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 119,856 shares of the company's stock valued at $296,000 after buying an additional 85,938 shares in the last quarter. 70.37% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对该公司的持股。AQR Capital Management LLC 在第一季度将其在 Prime Medicine 的持股比例提高了 1,419.4%。AQR Capital Management LLC 目前拥有 243,795 股该公司的股票，价值 48.5 万美元，此前在此期间购买了额外的 227,749 股。Jacobs Levy Equity Management Inc. 在第一季度购买了 Prime Medicine 的新头寸，价值约为 101,000 美元。Rhumbline Advisers 在第一季度将其在 Prime Medicine 的持股比例提高了 13.8%。Rhumbline Advisers 目前拥有 81,900 股该公司的股票，价值 163,000 美元，此前在此期间购买了额外的 9,944 股。Creative Planning 在第二季度购买了 Prime Medicine 的新股份，价值约为 25,000 美元。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 在第二季度将其在 Prime Medicine 的持股比例提高了 253.4%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 目前拥有 119,856 股该公司的股票，价值 29.6 万美元，此前在上个季度购买了额外的 85,938 股。当前 70.37% 的股票由机构投资者持有。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>关于 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.</p>
<div class="lb-trans"><p>我们是一家生物技术公司，致力于提供一种新型的差异化一次性治愈性基因疗法——Prime Editors，以通过部署我们的 Prime Editing 技术来解决最广泛的疾病谱系。我们认为这是一种多功能、精确、高效且广泛的基因编辑技术。与疾病相关的基因突变多种多样，可能从单个碱基的错误（称为点突变）到超出单个碱基的错误，例如插入、缺失、重复或其组合。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Prime Medicine</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UFJNRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐现在购买，以便在更广泛的市场注意到之前……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中有 “适度买入” 的评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Prime Medicine (NASDAQ:PRME) Upgraded to Sell at Wall Street Zen

Market Beat

Prime Medicine

纳斯达克生物科技指数 ETF - iShares Nasdaq

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

2 倍做多纳斯达克生物技术 ETF - ProShares

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

奥本海默控股

Prime Medicine（纳斯达克代码：PRME）在 Wall Street Zen 被调升至卖出评级